Tychon Bioscience, Inc. Information

Tychon Biosciences is advancing precision cancer immunotherapy through a novel approach that transforms a patients immune cells into a PAR-T cell trained to find and eliminate cancer cells. Despite its promise as a new cancer treatment, clinical adoption of T-cell based immunotherapy has been slow due to a variety of shortcomings. Our therapy delivers on this promise by addressing these shortcomings with a novel approach. Our PAR-T technology can be used as a primary therapy or in combination with other therapies, opening up enormous untapped potential to treat early and late-stage cancers. A protein-based drug that activates your T-cells to find and eliminate cancer.